Lancet Oncology Managing Editor David Collingridge and ICGC Executive Director Andrew Biankin announcing the kick-off of the ICGC at the 18th ICGC Scientific Workshop
At the 18th Scientific Workshop in Verona earlier this month ICGC ARGO announced it would be establishing a new commission project in Cancer ‘Omics and Precision Medicine, as part of the Lancet Oncology Commission Programme.
Through the programme of Commissions, The Lancet Oncology has worked with partners to address some of the most pressing unmet needs in oncology—across medicine, science, social science, global health, and health policy—with the aim of providing recommendations that improve clinical practice, change health policy, or more generally, enhance cancer control.
ICGC ARGO will be leading this latest Commission that will focus on cancer genomics and precision medicine. This commission will bring together international experts and stakeholders who have expertise across a range of priority issues that collectively define how cancer ‘omics can be implemented in a more sustainable and accessible way; be shared more widely; and be better used for the benefit of people affected by cancer. It will explore areas of cancer molecular testing, omics data that can improve cancer care, and precision medicine. The project aims to propose solutions to assist health systems worldwide deliver streamlined, equitable, and effective molecular-based cancer care.
We look forward to sharing more about this project in the future as work progresses.